News from bexion pharmaceuticals, inc. A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Feb 22, 2021, 15:20 ET Bexion Pharmaceuticals Announces the Addition of Olivia F. Kirtley to Board of Directors

Bexion Pharmaceuticals, Inc. announced today that it has added Olivia F. Kirtley to its Board of Directors. Ms. Kirtley, a Certified Public...

Nov 17, 2020, 10:33 ET Bexion Pharmaceuticals Announces the Addition of Dr. Raymond J. Tesi to Board of Directors

Bexion Pharmaceuticals, Inc. announced today that it has added RJ. Tesi, M.D. to its Board of Directors. Dr. Tesi has a distinguished career as a...

May 13, 2020, 10:53 ET Bexion Pharmaceuticals Presenting BXQ-350 Data at ASCO 2020

Bexion Pharmaceuticals announced today that the following three abstracts submitted to the 2020 American Society of Clinical Oncology (ASCO) have...

May 07, 2020, 11:33 ET Bexion Pharmaceuticals Receives Orphan Drug Designation for BXQ-350 for Malignant Glioma from FDA

Bexion Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted the company Orphan Drug Designation for its ...

Jul 30, 2019, 08:43 ET Significant Regulatory Milestone Towards Phase 2 in Recurrent GBM

Bexion Pharmaceuticals, Inc. an oncology-focused company today announced the completion of a Type B End-of-Phase 1 meeting with the U.S. Food and...

May 23, 2019, 09:09 ET Robert G. Savage Added to Bexion's Board of Directors

Bexion Pharmaceuticals, Inc. (Bexion) announced today that the company has added Bob Savage, MBA to its Board of Directors. Mr. Savage brings to the...

Apr 30, 2019, 08:48 ET Bexion Pharmaceuticals Increases Series B to $25MM

Bexion Pharmaceuticals, Inc. (Bexion) announced today that the Board of Directors and shareholders approved the increase of the Series B Preferred...

Mar 05, 2019, 09:07 ET Bexion Pharmaceuticals Experiences Robust Enrollment of Phase I Part 3 First-In-Human Trial Using BXQ-350 for the Treatment of Cancer

Bexion Pharmaceuticals, Inc. (Bexion) announced today Part 3 of their Phase I First-In-Human Trial using BXQ-350 for the treatment of cancer has...

Feb 22, 2019, 09:21 ET Bexion Pharmaceuticals Announces the Opening of Phase I Part 3 First-in-Human Trial Using BXQ-350 for the Treatment of Cancer

Bexion Pharmaceuticals, Inc. (Bexion) announced today the opening of Part 3 of their Phase I First-In-Human Trial using BXQ-350 for the treatment of...